AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21904839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 36
Study 21144969 — intervention group
Group type: EXPERIMENTAL
Intervention: Management guided by individualized NT-proBNP target
Number of subjects: 345
Study 21144969 — intervention group
Group type: COMPARATOR
Intervention: Clinically-guided outpatient management
Number of subjects: 345
Study 17432677 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Daotan Decoction (DD) + risperidone 3.16 +/- 0.73 mg/d
Number of subjects: 65
Study 17432677 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 5.11 +/- 1.27 mg/d
Number of subjects: 65
Study 11124171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 0
Study 11124171 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0
Study 11124171 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 0
Study 11124171 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial enzymatic stain remover
Number of subjects: 0
Study 11124171 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 9066933 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 18
Study 9066933 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 250 mg
Number of subjects: 18
Study 8378946 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/d
Number of subjects: 24
Study 8378946 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (INR 2.0 to 4.5)
Number of subjects: 24
Study 2947148 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine 60 mg
Number of subjects: 10
Study 2947148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29180306 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue
Number of subjects: 99
Study 29180306 — intervention group
Group type: COMPARATOR
Intervention: Control (nonpharmacologic treatment)
Number of subjects: 99
Study 25720763 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes management initiated within 1 week of diagnosis
Number of subjects: 67
Study 25720763 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study 25539671 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based intervention to improve skin self-examination (SSE) behaviour
Number of subjects: 831
Study 25539671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 831
Study 22588635 — intervention group
Group type: EXPERIMENTAL
Intervention: whey hydrolysate (hydro-meal)
Number of subjects: 12
Study 22588635 — intervention group
Group type: EXPERIMENTAL
Intervention: whey isolate (iso-meal)
Number of subjects: 12
Study 22588635 — intervention group
Group type: EXPERIMENTAL
Intervention: lac-meal
Number of subjects: 12
Study 22588635 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMP-meal
Number of subjects: 12
Study 22588635 — intervention group
Group type: COMPARATOR
Intervention: whey protein fractions
Number of subjects: 12
Study 20297744 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with alcohol-based hand sanitizer
Number of subjects: 509
Study 20297744 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with hand sanitizer and face masks
Number of subjects: 509
Study 20297744 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 509
Study 20297744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Sanitizer
Number of subjects: 509
Study 20297744 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask wearing
Number of subjects: 509
Study 18790556 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical form crown
Number of subjects: 19
Study 18790556 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat occlusal table with occlusal contacts
Number of subjects: 19
Study 18790556 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat occlusal table without occlusal contacts
Number of subjects: 19
Study 18790556 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of crowns
Number of subjects: 19
Study 15689764 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with adrenaline (1:200,000)
Number of subjects: 76
Study 15689764 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline with adrenaline (1:200,000)
Number of subjects: 76
Study 15689764 — intervention group
Group type: COMPARATOR
Intervention: Saline without adrenaline
Number of subjects: 76
Study 14559892 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative AC followed by docetaxel
Number of subjects: 2411
Study 14559892 — intervention group
Group type: COMPARATOR
Intervention: Preoperative AC alone
Number of subjects: 2411
Study 10648489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil 50 mg twice daily
Number of subjects: 203
Study 10648489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil 100 mg twice daily
Number of subjects: 203
Study 10648489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedisamil 150 mg twice daily
Number of subjects: 203
Study 10648489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 8878350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.6 micrograms/kg IV)
Number of subjects: 14
Study 8878350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8878350 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 14
Study 1281648 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-PAR in patients with advanced breast cancer
Number of subjects: 619
Study 1281648 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen treatment in receptor-defined subgroups
Number of subjects: 619
Study 1281648 — intervention group
Group type: COMPARATOR
Intervention: ER-DCC and ER-PAR comparison
Number of subjects: 619
Study 1281648 — intervention group
Group type: COMPARATOR
Intervention: ER-ICA and ER-DCC correlation
Number of subjects: 619
Study 1281648 — intervention group
Group type: COMPARATOR
Intervention: ER-PAR prognostic value
Number of subjects: 619
Study 31710345 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE Steps to Success Program
Number of subjects: 551
Study 31710345 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 551
Study 30993423 — intervention group
Group type: EXPERIMENTAL
Intervention: High cumulative dose of DMF exposure
Number of subjects: 672
Study 30993423 — intervention group
Group type: EXPERIMENTAL
Intervention: GOT2 gene polymorphism (rs7204324)
Number of subjects: 672
Study 30993423 — intervention group
Group type: COMPARATOR
Intervention: CYP2E1 gene polymorphisms (rs2031920, rs3813867, rs6413432)
Number of subjects: 672
Study 26471495 — intervention group
Group type: EXPERIMENTAL
Intervention: GDFT (Goal Directed Fluid Therapy)
Number of subjects: 120
Study 26471495 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (no-protocol treatment)
Number of subjects: 120
Study 23413771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 23413771 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study 21220060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 215
Study 21220060 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 215
Study 19552020 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisubstrate nutritional cocktail (0.3 g/kg protein weight, 7.5 g fibers per day, 10 kcal/kg body weight) in addition to conventional treatment.
Number of subjects: 61
Study 19552020 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (lactulose, beta-blocker, spironolactone based on 1.2 g/kg protein weight and 30 kcal/kg body weight per day).
Number of subjects: 61
Study 18572750 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir 1,600/100 mg per day plus two NRTIs
Number of subjects: 272
Study 15762881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae
Number of subjects: 12
Study 12092000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (Quixil) - 0.3 ml sprayed to each bleeding nostril
Number of subjects: 204
Study 12092000 — intervention group
Group type: COMPARATOR
Intervention: Electric cautery
Number of subjects: 204
Study 12092000 — intervention group
Group type: COMPARATOR
Intervention: Silver nitrate coagulation
Number of subjects: 204
Study 12092000 — intervention group
Group type: COMPARATOR
Intervention: Foam nasal packing
Number of subjects: 204
Study 10363623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% netilmicin ophthalmic solution
Number of subjects: 45
Study 10363623 — intervention group
Group type: COMPARATOR
Intervention: 0.3% tobramycin
Number of subjects: 45
Study 7491392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.25 mg/kg)
Number of subjects: 17
Study 7491392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1664978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (daily injection)
Number of subjects: 204
Study 1664978 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 204
Study 1664978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (in patients with fractures)
Number of subjects: 204
Study 1664978 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group in patients with fractures)
Number of subjects: 204
Study 7071793 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage (up to 20 cm H2O pressure)
Number of subjects: 53
Study 7071793 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage
Number of subjects: 53
Study 7071793 — intervention group
Group type: EXPERIMENTAL
Intervention: Early catheter removal (as soon as the lung was expanded)
Number of subjects: 53
Study 7071793 — intervention group
Group type: COMPARATOR
Intervention: Late catheter removal (catheters left in situ for a further three days)
Number of subjects: 53
Study 31229205 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical massage (CMG) before each paclitaxel infusion
Number of subjects: 40
Study 31229205 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical massage (CMG)
Number of subjects: 40
Study 31229205 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) receiving usual care
Number of subjects: 40
Study 28608394 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 33
Study 28608394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic beer (na-beer)
Number of subjects: 33
Study 28608394 — intervention group
Group type: EXPERIMENTAL
Intervention: Gin
Number of subjects: 33
Study 28608394 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer and nonalcoholic beer (na-beer)
Number of subjects: 33
Study 26494562 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention including a primary care electronic CKD registry and a language-concordant self-management support program.
Number of subjects: 0
Study 23524688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel with BMP-2 (250 µg/mL)
Number of subjects: 12
Study 23524688 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel alone
Number of subjects: 12
Study 23524688 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel with autograft
Number of subjects: 12
Study 23524688 — intervention group
Group type: COMPARATOR
Intervention: Spongostan (negative control)
Number of subjects: 12
Study 23524688 — intervention group
Group type: COMPARATOR
Intervention: Tisseel mixed with bone autograft (control group)
Number of subjects: 12
Study 21509444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 11140
Study 21509444 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study 19452730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy and adenoidectomy
Number of subjects: 61
Study 19452730 — intervention group
Group type: COMPARATOR
Intervention: Tonsillar and adenoidal hypertrophy (compared to control children)
Number of subjects: 61
Study 17869307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tookad vascular targeted photodynamic therapy (0.1 to 2 mg/kg) with a fixed light dose of 100 J/cm
Number of subjects: 6
Study 17869307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tookad vascular targeted photodynamic therapy (2 mg/kg) with escalated light doses of 230 and 360 J/cm
Number of subjects: 6
Study 17869307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tookad vascular targeted photodynamic therapy
Number of subjects: 6
Study 15650343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus statin (lovastatin, pravastatin, simvastatin, atorvastatin)
Number of subjects: 1861
Study 15650343 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy (lovastatin or pravastatin 10, 20, or 40 mg; simvastatin or atorvastatin 10, 20, 40, or 80 mg)
Number of subjects: 1861
Study 11589675 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg per day for 4 months (n = 14)
Number of subjects: 32
Study 11589675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 32
Study 9626926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegretol (branded carbamazepine)
Number of subjects: 12
Study 9626926 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ Pharmachemie (generic carbamazepine)
Number of subjects: 12
Study 9626926 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ Pharbita (generic carbamazepine)
Number of subjects: 12
Study 9626926 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 12
Study 7884977 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory group (n=25)
Number of subjects: 49
Study 7884977 — intervention group
Group type: COMPARATOR
Intervention: Impression group (n=24)
Number of subjects: 49
Study 3126350 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue‐type plasminogen activator (rt‐PA) 80 mg
Number of subjects: 100
Study 3126350 — intervention group
Group type: COMPARATOR
Intervention: streptokinase (SK) 1.5 million units
Number of subjects: 100
Study 3126350 — intervention group
Group type: EXPERIMENTAL
Intervention: old rt‐PA 80 mg
Number of subjects: 100
Study 3126350 — intervention group
Group type: EXPERIMENTAL
Intervention: new rt‐PA 80 mg
Number of subjects: 100
Study 3126350 — intervention group
Group type: EXPERIMENTAL
Intervention: new rt‐PA 100 mg
Number of subjects: 100
Study 3126350 — intervention group
Group type: EXPERIMENTAL
Intervention: new rt‐PA 150 mg
Number of subjects: 100
Study 3126350 — intervention group
Group type: EXPERIMENTAL
Intervention: new rt‐PA (various doses)
Number of subjects: 100
Study 29128787 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct and indirect handwashing interventions
Number of subjects: 0
Study 29128787 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 0
Study 29128787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 0
Study 26679894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 510
Study 26679894 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 510
Study 25622920 — intervention group
Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 20
Study 25622920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract-Relax Stretching (CRS)
Number of subjects: 20
Study 23073817 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical incision
Number of subjects: 120
Study 23073817 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 120
Study 23073817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique incision
Number of subjects: 120
Study 23073817 — intervention group
Group type: COMPARATOR
Intervention: Control (Transverse and Oblique)
Number of subjects: 120
Study 20386144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) with rabbit antithymocyte globulin induction
Number of subjects: 141
Study 20386144 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 141
Study 17655971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixing grapefruit juice with sucrose
Number of subjects: 111
Study 17655971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixing broccoli or cauliflower with sugar
Number of subjects: 111
Study 15737106 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 5
Study 15737106 — intervention group
Group type: COMPARATOR
Intervention: conventional antipsychotic agents
Number of subjects: 5
Study 11972144 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with high frequencies (above 5 Hz) applied to the left dorsolateral prefrontal cortex
Number of subjects: 0
Study 11972144 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with low frequencies applied to the right dorsolateral prefrontal cortex
Number of subjects: 0
Study 10599054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor metrifonate (MTF) treatment for 6 months
Number of subjects: 12
Study 10599054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor metrifonate (MTF) treatment for 2 years or more
Number of subjects: 12
Study 10599054 — intervention group
Group type: COMPARATOR
Intervention: No treatment (off MTF)
Number of subjects: 12
Study 10599054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor metrifonate (MTF) treatment
Number of subjects: 12
Study 7487242 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational brochure and encouragement to execute durable health care proxies
Number of subjects: 162
Study 7487242 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 162
Study 1773579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for dosing warfarin
Number of subjects: 65
Study 1773579 — intervention group
Group type: COMPARATOR
Intervention: Computer program for dosing warfarin
Number of subjects: 65
Study 1773579 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured PTR
Number of subjects: 65
Study 7053286 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs prescribed to 63% of patients
Number of subjects: 230
Study 7053286 — intervention group
Group type: EXPERIMENTAL
Intervention: More vigorous treatments prescribed
Number of subjects: 230
Study 7053286 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient compliance with treatment
Number of subjects: 230
Study 7053286 — intervention group
Group type: EXPERIMENTAL
Intervention: Product of prescribed vigor and compliance
Number of subjects: 230
Study 31955271 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 30
Study 31955271 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel crowns
Number of subjects: 30
Study 29110574 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Therapy (MT)
Number of subjects: 307
Study 29110574 — intervention group
Group type: COMPARATOR
Intervention: Surgical Treatment (ST)
Number of subjects: 307
Study 25533021 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined individual dietary counseling with individualized swallowing therapy
Number of subjects: 120
Study 25533021 — intervention group
Group type: COMPARATOR
Intervention: Individual dietary counseling
Number of subjects: 120
Study 24832727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary grape powder
Number of subjects: 24
Study 24832727 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 24
Study 23972414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for relatively active patients
Number of subjects: 60
Study 23972414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for passive patients
Number of subjects: 60
Study 23972414 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60
Study 20569761 — intervention group
Group type: EXPERIMENTAL
Intervention: STAFF
Number of subjects: 9835
Study 20569761 — intervention group
Group type: EXPERIMENTAL
Intervention: AUTO
Number of subjects: 9835
Study 20569761 — intervention group
Group type: COMPARATOR
Intervention: NONE
Number of subjects: 9835
Study 18761065 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin-5'-phosphate sodium salt (RF5P) delivered via gastro-mucoadhesive delivery system based on ion-exchange fiber; specific dosage and duration not mentioned.
Number of subjects: 0
Study 18761065 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dissolution system (flow through diffusion cell) used to study drug release; specific details not mentioned.
Number of subjects: 0
Study 18761065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal transit studies in rats; specific details not mentioned.
Number of subjects: 0
Study 18761065 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma imaging study in human volunteers; specific details not mentioned.
Number of subjects: 0
Study 18761065 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of urinary excretion of riboflavin in humans; specific details not mentioned.
Number of subjects: 0
Study 16822237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4 g/day)
Number of subjects: 83
Study 16822237 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation (4 g/day)
Number of subjects: 83
Study 12814446 — intervention group
Group type: EXPERIMENTAL
Intervention: 08.00 h dosing of 3 micro g oral vitamin D3
Number of subjects: 13
Study 12814446 — intervention group
Group type: COMPARATOR
Intervention: 20.00 h dosing of 3 micro g oral vitamin D3
Number of subjects: 13
Study 10888694 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational computer program, Asthma Control
Number of subjects: 137
Study 10888694 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials with a research assistant
Number of subjects: 137
Study 8740611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 8740611 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drugs
Number of subjects: 525